These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 28851512)

  • 1. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
    Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A
    Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan.
    Ida H; Watanabe Y; Sagara R; Inoue Y; Fernandez J
    Orphanet J Rare Dis; 2022 Nov; 17(1):401. PubMed ID: 36329499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations.
    Dinur T; Grittner U; Revel-Vilk S; Becker-Cohen M; Istaiti M; Cozma C; Rolfs A; Zimran A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy.
    Dubiela P; Szymanska-Rozek P; Hasinski P; Lipinski P; Kleinotiene G; Giersz D; Tylki-Szymanska A
    Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062556
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
    Hurvitz N; Dinur T; Becker-Cohen M; Cozma C; Hovakimyan M; Oppermann S; Demuth L; Rolfs A; Abramov A; Zimran A; Revel-Vilk S
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.
    Revel-Vilk S; Fuller M; Zimran A
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
    Dinur T; Bauer P; Beetz C; Kramp G; Cozma C; Iurașcu MI; Becker-Cohen M; Istaiti M; Rolfs A; Zimran A; Revel-Vilk S
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review.
    Giuffrida G; Markovic U; Condorelli A; Calafiore V; Nicolosi D; Calagna M; Grasso S; Ragusa MTV; Gentile J; Napolitano M
    Orphanet J Rare Dis; 2023 Feb; 18(1):27. PubMed ID: 36782327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease.
    Dinur T; Bauer P; Beetz C; Cozma C; Becker-Cohen M; Istaiti M; Rolfs A; Skrahina V; Zimran A; Revel-Vilk S
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots.
    Cozma C; Cullufi P; Kramp G; Hovakimyan M; Velmishi V; Gjikopulli A; Tomori S; Fischer S; Oppermann S; Grittner U; Bauer P; Beetz C; Rolfs A
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
    Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucosylsphingosine Causes Hematological and Visceral Changes in Mice-Evidence for a Pathophysiological Role in Gaucher Disease.
    Lukas J; Cozma C; Yang F; Kramp G; Meyer A; Neßlauer AM; Eichler S; Böttcher T; Witt M; Bräuer AU; Kropp P; Rolfs A
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29053611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
    Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.
    Vernet Machado Bressan Wilke M; Iop GD; Faqueti L; Lemos da Silva LA; Kubaski F; Poswar FO; Michelin-Tirelli K; Randon D; Borelli WV; Giugliani R; Schwartz IVD
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS/MS.
    Tang C; Jia X; Tang F; Liu S; Jiang X; Zhao X; Sheng H; Peng M; Liu L; Huang Y
    Clin Biochem; 2021 Jan; 87():79-84. PubMed ID: 33188770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study.
    Curado F; Rösner S; Zielke S; Westphal G; Grittner U; Skrahina V; Alasel M; Malik AM; Beetz C; Böttcher T; Barel G; Sah AP; Dinur T; Anjum N; Ichraf Q; Kriouile Y; Hadipour Z; Hadipour F; Revel-Vilk S; Cozma C; Hartkamp J; Cheema H; Zimran A; Bauer P; Rolfs A;
    Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucosylsphingosine (Lyso-Gb
    Gayed MM; Jung SH; Huggins E; Rodriguez-Rassi E; DeArmey S; Kishnani PS; Stiles AR
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.